LAVAL, QC, June 4 /CNW Telbec/ - Neptune Technologies & Bioressources
Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) today announced that it has signed
an agreement with Bayer Healthcare, LLC for the commercialization of Neptune
proprietary products in the United States.
"The signing of this agreement with a partner of the caliber of Bayer
supports Neptune's business and scientific choice to pursue the more demanding
and challenging clinical development path of assessing safety and
effectiveness of its products. As planned, it has been strategic to invest the
time and resources into building a complete portfolio of scientific data,
intellectual property and regulatory approvals which ultimately allowed the
Company to attract the best partner," stated Dr. Tina Sampalis, Chief
Scientific Officer of Neptune.
"Neptune's approach to commercialization consists of rapidly penetrating
the market to generate short-term revenue and growth by partnering with the
right marketer that can create broad consumer awareness leveraged by our
substantial scientific data and that can create large market share for
Neptune. Bayer is among the world's largest marketers of healthcare products,"
"Through the capabilities, reputation and commitment of its partners
favoring growth, Neptune leverages and maximizes value by opening doors for
future product and business development opportunties developed by Neptune and
its pharmaceutical subsidiaries," stated Mr. Henri Harland, Chief Executive
Officer and President of Neptune. "The parallel stepwise approach of exploring
other future products and project opportunities directed towards
pharmaceutical driven applications is part of the plan," he added.
"Under Neptune's strategic vision, which has been pursued since the
beginning of its operations, the Company has anticipated to penetrate world
nutraceutical and pharmaceutical markets in collaboration with global
international partners. The alliance with Bayer in the United States
represents another important milestone in the execution of our strategic
development plan by the team, so we are moving in the right direction," he
About Neptune Technologies & Bioressources Inc.
Neptune is an industry-recognized leader in the innovation, production
and formulation of science-based and clinically-proven novel phospholipid
products for the nutraceutical and pharmaceutical markets. The Company focuses
on growing consumer health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive approach to
managing health and preventing disease. The Company carries out clinical
trials to show the therapeutic benefits in various medical indications and to
obtain regulatory approval for health claims. Neptune is continuously
expanding its portfolio of intellectual property, clinical studies, regulatory
approvals and health claims. Neptune has its products marketed and distributed
in over 20 countries worldwide.
NASDAQ does not accept responsibility for the adequacy or accuracy of
this press release. Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of
Statements in this press release that are not statements of historical or
current fact, including statments relating to the Company's expectation
regarding the future performance and marketability of its products, constitute
"forward-looking statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of the Company to be
materially different from historical results or from any future results
expressed or implied by such forward-looking statements. In addition to
statements which explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates,"should," "will" or "plans" to be uncertain
and forward-looking. The forward-looking statements contained herein are also
subject generally to other risks and uncertainties that are described from
time to time in the Company's reports filed with the Securities and Exchange
Commission and the Canadian securities commissions.
For further information:
For further information: Toni Rinow, Ph.D., MBA, Corporate Development &
Investor Relations, Neptune Technologies & Bioressources Inc., (450) 687-2262,
email@example.com; www.neptunebiotech.com; Source: Neptune
Technologies & Bioressources Inc.